Atlas Trials

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Clinical trial NCT04677595 · COMPLETED

Trial details

NCT number
NCT04677595
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer (NSCLC)
Start date
2021-05-17
Primary completion
2023-10-12
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.